5Wirshing DA, Pierre JM, Erhart SM, et al. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psy- chiat clin North Am,2003,26( 1 ) : 165-190.
6Lalonde P. Evaluating antipsychotic medications: predictors of clin- ical effectiveness. Can J Psychiatry ,2003,48 ( 3 Suppl 11 ) :3-12.
2Schmitt HP.On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease.Med Hypotheses,2005,65:259-265.
3Reisberg B,Doody R,Stoffler A,el al.A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.Arch Neurol,2006,63:49-54.
4Birks J,Harvey RJ.Donepezil for dementia due to Alzheimer's disease.Cochrane Database Syst Rev,2006,25:CD001190.
5Tariot PN,Farlow MR,Grossberg GT,et al.Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil:a randomized controlled trial.JAMA,2004,291:317-324.
6Peskind ER,Potkin SG,Pomara N,et al.Memantine treatment in mild to moderate Alzheimer disease:a 24-week randomized,controlled trial.Am J Geriatr Psychiatry,2006,14:704-715.
7Bakchine S,Loft H.Memantine treatment in patients with mild to moderate Alzheimer's disease:results of a randomised,double-blind,placebo-controlled 6-month study.J Alzheimers Dis,2008,13:97-107.
8Davis KL,Mohs RC,Marin D,et aI.Cholinergic markers in elderly patients with early signs of Alzheimer disease.JAMA,1999,281:1401-1406.
9Johnson JW,kotermanski SE.Mechanism of action of memantine.Curr Opin Pharmacol,2006,6:61-67.
10Farlow MR,Graham SM,Alva G.Memantine for the treatment of Alzheimer's disease:tolerability and safety data from clinical trials.Drug Saf,2008,31:577-585.
4Harvey PD, Green MF, Bowie C, et al. The dimensions of clinical and cognitive change in schizophrenia:evidence for independence of improvements. Psychopharmacology ( Berl ), 2006, 187 ( 3 ) : 356-363.
5Green MF, Nuechtedein KH, Gold JM,et al. Approaching a con- sensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry,2004,56 ( 5 ) :301-307.
6Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in sehizophrenia:are we measuring the "fight stuff". Sehizophr Bu11,2000,26 ( 1 ) : 119-136.
7Green MF, Nuechterlein KH. Should schizophrenia be treated as a neurocognitive disorder?. Schizophr Bull, 1999,25 ( 2 ) : 309 -319.
8Medalia A, Lim R. Treatment of cognitive dysfunction in psychiat- ric disorders. J Psychiatr Pract,2004,10( 1 ) : 17-25.
9Harvey PD, Green MF, Keefe RS, et al. Cognitive functioning in schizophrenia: a cohsensus statement on its role in the definition and evaluation of effective treatments for the illness. Clin Psychia- try,2004,65 ( 3 ) :361-372.
10Weiser M,Scheider-Beer M, Nakash N, et ai. Impromentin cogni- tion as sociated with nove antipsychotic drugs:a direct drug effec- tor reduction of EPS. Schizophr Res ,2000,46 ( 2-3 ) :81-89.
